Business Wire

PUMA Made 7 Out of 10 Products from Better Materials In 2022

24.5.2023 12:28:00 EEST | Business Wire | Press release

Share

Sports company PUMA made 7 out of 10 products from better materials in 2022, according to the company’s Sustainability Report 2022, as it further scaled up the use of recycled materials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005783/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sports company PUMA has made 7 out of 10 products from better materials in 2022, according to the company’s Sustainability Report 2022, as it further scaled up the use of recycled materials. (Photo: Business Wire)

Better materials, such as cotton and viscose from certified sources or recycled polyester, have a smaller environmental footprint in terms of CO2 emissions and allow PUMA to improve its environmental impact across its product range. Since 2017, we have been able to reduce PUMA’s CO2 emissions from materials by 32%. Overall CO2 emissions could be reduced by 7%*, despite a significant growth in sales..

“Our Forever Better strategy aims to make PUMA better across the entire value chain, whether it comes to materials, carbon emissions, circularity or human rights,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We know there is still a lot of work to be done, but we are encouraged by the progress we made last year.”

While PUMA, which is on track to reach its goal of making 9 out of 10 products with better materials by 2025, continued to power 100%* of its offices, stores and warehouses with renewable energy in 2022, its suppliers also increased the use of renewable energy in the supply chain, where most of PUMA’s carbon emissions originate.

PUMA’s core suppliers, which represent approximately 80% of PUMA’s production volume, more than doubled their consumption of renewable energy in just one year, from 0.2% in 2017 to 11% in 2022. This was achieved through the installation of large-scale solar power systems at selected suppliers and the purchase of renewable energy certificates. By 2025, PUMA aims to more than double this figure once again and get its core suppliers to source a quarter of their energy needs from renewable sources.

More than 50% of the polyester used in PUMA’s apparel and accessories came from recycled materials and the company also started to scale up the use of recycled cotton.

At the same time, PUMA made progress with its Forever Better experiments RE:SUEDE, which tests for a biodegradable sneaker, and RE:FIBRE, which aims to scale up more advanced polyester recycling technologies. Both projects continue in 2023.

To ensure that the rights of the more than half a million workers in PUMA’s supply chain were upheld, the company collected audit reports from 510 factories producing finished products and materials in 2022.

PUMA’s sustainability report is available at https://annual-report.puma.com.. As a result of the feedback PUMA received during its first “Conference of the People” in London in 2022 and to reach out to young audiences, parts of the sustainability report will also be made available as a podcast on Spotify, launching June 1, 2023.

*Including renewable energy attribute certificates

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kerstin Neuber - Corporate Communications - PUMA SE - Kerstin.neuber@puma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye